- Poster presentation
- Open Access
Treatment planning and patient positioning for MR-guided high intensity focused ultrasound treatment: a systematic approach
© Kinnaird et al; licensee BioMed Central Ltd. 2015
- Published: 30 June 2015
- Focus Ultrasound
- Total Treatment Time
- High Intensity Focus Ultrasound
- Coordinate Algorithm
- Prolonged Anesthesia
Treatment duration as well as time spent on patient positioning imposes limitations on therapeutic use of MR-guided High Intensity Focused Ultrasound (MR-HIFU). Reduction of overall treatment time is especially important in potential pediatric applications and in other cases where general anesthesia must be used, due to the risks associated with prolonged anesthesia. Typically, up to 4 hours are allotted for the procedure, with patient positioning and treatment planning requiring an hour or more. If re-positioning is required during treatment, acquisition of needed images and re-planning of treatment may require 30 minutes or longer before ablation can resume. These delays limit the total time allowed for treatment, limiting the size of tumors that can be treated and increasing the risks as well as the cost of the procedure. The aim of this study is to evaluate the information needed to accurately plan MR-HIFU ablation of solid extremity tumors and to rationally design a practical approach to patient positioning for such treatments.
Correct positioning of a tumor-bearing limb was accomplished via three methods that rely on three-dimensional segmentation of pre-procedural MR images: 1) a printed, concise, patient-specific guide that shows all steps necessary for optimal patient positioning, 2) a printed or projected grid that is spatially referenced to the printed guide, and 3) a patient-specific ultrasound stand-off gel pad that accurately orients the targeted extremity relative to the center of the MR-HIFU tabletop membrane. Especially complex cases from a set of 41 patients were examined in development of these methods. Performance characteristics of one of the MR-HIFU devices currently in clinical trials, the Philips Sonalleve V2 (Philips Healthcare, Vantaa, Finland) were used.
Funding was provided by the Sheikh Zayed Institute at Children’s National Medical Center in Washington, D.C.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.